September 16, 2021 9:38 AMThe Series C fund-raising round was led by US-based healthcare-focused venture capital firm Arboretum Ventures. : SINGAPORE (THE BUSINESS TIMES) - Allay Therapeutics, a clinical-stage biotech start-up that makes pain relief products, raised US$60 million (S$80.45 million) in a Series C fund-raising round led by United States-based healthcare-focused venture capital firm Arboretum Ventures. Temasek, Temasek's subsidiary Pavilion Capital, as well as Temasek-linked Vertex Growth and Vertex Ventures HC participated in the round; there was no shortage of other crossover investors, including from Australia and Taiwan.